de

/

eng
immunotherapy

The good thing about immunotherapy is that it is so specific. Only the cell structure that is to be attacked is attacked.

The less precisely a treatment is targeted, the more side effects it causes, including the collateral damage that occurs with chemotherapy. Even with targeted therapies, the problem exists that the structures that are found and attacked more in tumours are also found in normal cells - they are exposed to the same destructive attacks. This effect does not exist in the specific treatment form of cellular immunotherapy.

Another special feature of the therapy is that a part of the informed immune cells migrates into the bone marrow and forms an immunological memory there. It can prevent the development of metastases, which often remain undetected in early stages. As soon as the tumour cells become active again, the immune system is able to keep the growth of the tumour in check on its own because it is capable of learning.

Privately and publicly funded clinical trials worldwide

2022: There are more than 90,000 international studies on oncology but only about 5 percent deal with the special segment of immunotherapy against cancer. Due to the individualised form of treatment, it does not promise high profits from a possible mass product.

Therefore, it is all the more important to support private initiatives that support research into this innovative form of therapy and advance the external communication of this topic.